The week started with quite an interesting development – Merck and Glenmark were to mediate in the Januvia (Sitagliptin) patent infringement case. Madhulika reported on this, her post covering a brief history of the dispute, as well as making an important observation as to the trend of mediation being in vogue in patent cases. The other similar example that she points to is the Roche-Cipla case. She also points to the potential anti-trust implications that patent settlements might have. Swaraj...
↧